2. Academic Validation
  3. Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma

Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma

  • J Biol Chem. 2024 Mar 21:107208. doi: 10.1016/j.jbc.2024.107208.
Cheng Zhang 1,  Wenjing Wei 2,  Shuo Tu 2,  Bo Liang 3,  Chun Li 4,  Yining Li 2,  Weicheng Luo 2,  Yiqing Wu 2,  Xiaohui Dai 2,  Yi Wang 2,  Lijuan Zheng 2,  Liang Hao 3,  Chunbo Zhang 5,  Zhijun Luo 6,  Ye-Guang Chen 7,  Xiaohua Yan 8
Affiliations

Affiliations

  • 1 The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China;; The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 2 The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 3 The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 4 The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 5 School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 6 Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 7 The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China;; School of Life Sciences, Tsinghua University, Beijing, China.
  • 8 The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, Jiangxi Medical College, Nanchang University, Nanchang, China;; The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China;. Electronic address: yanxiaohua@ncu.edu.cn.
PMID: 38521502 DOI: 10.1016/j.jbc.2024.107208
Abstract

TGF-β and Hippo signaling are two critical pathways engaged in Cancer progression by regulating both oncogenes and tumor suppressors, yet how the two pathways coordinately exert their functions in the development of hepatocellular carcinoma (HCC) remains elusive. In this study, we firstly conducted an integrated analysis of public liver Cancer databases and our experimental TGF-β target genes, identifying CYR61 as a pivotal candidate gene relating to HCC development. The expression of CYR61 is downregulated in clinical HCC tissues and cell lines than that in the normal counterparts. Evidence revealed that CYR61 is a direct target gene of TGF-β in liver Cancer cells. In addition, TGF-β-stimulated SMAD2/3 and the Hippo pathway downstream effectors YAP and TEAD4 can form a protein complex on the promoter of CYR61, thereby activating the promoter activity and stimulating CYR61 gene transcription in a collaborative manner. Functionally, depletion of CYR61 enhanced TGF-β- or YAP-mediated growth and migration of liver Cancer cells. Consistently, ectopic expression of CYR61 was capable of impeding TGF-β- or YAP-induced malignant transformation of HCC cells in vitro, and attenuating HCC xenograft growth in nude mice. Finally, transcriptomic analysis indicates that CYR61 can elicit an antitumor program in liver Cancer cells. Together, these results add new evidence for the crosstalk between TGF-β and Hippo signaling and unveil an important tumor suppressor function of CYR61 in liver Cancer.

Keywords

CYR61; Hepatocellular carcinoma; Signaling crosstalk; TGF-β; Transcriptional regulation; YAP/TEAD4.

Figures
Products